Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2020

View Archived Issues

After injury, astrocytes can make interneurons

First patient enrolled in study of plasma-derived IgG product as treatment of COVID-19 in Israel

CAR T cells targeting CD30 safe and active in patients with Hodgkin's lymphoma

Efficient CNS microglia replacement strategy developed

First-in-human data for anti-miR-92a therapy, MRG-110

Smoking and COPD are associated with increased ACE2 in alveolar and bronchial epithelium

SCO-094 enters phase I testing in patients with type 2 diabetes mellitus

Pivotal CheckMate-649 and CheckMate-577 studies of Opdivo meet primary endpoints

Medshine Discovery discloses new TGFBR1 inhibitors

New NLRP3 inflammasome inhibitors discovered at NodThera

Camphor Pharmaceuticals synthesizes new prostanoid EP4 receptor antagonists

FDA issues complete response letter for Pedmark

Ascentage Pharma, University of Michigan patent Mcl-1 inhibitors

5'-nucleotidase inhibitors discovered by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

Interim analysis data from ReDUX4 study of losmapimod in FSHD

Arcturus initiates dosing in phase I/II study of its COVID-19 vaccine candidate

Topline data presented from phase II study of leronlimab in mild to moderate COVID-19

Low-dose IL-2 shows potential for treating children with type 1 diabetes

New phase II trial explores use of M-5049 for COVID-19 pneumonia

FDA clears IND for phase I/II study of KAHR's DSP-107 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...